Nagpur-based biotech Startup ErlySign has announced a significant milestone in the fight against cancer with approval from the Indian regulatory agency CDSCO (Central Drugs Standard Control Organization) for its active salivary biomarker study designed for early cancer detection.

Following a comprehensive year-long investigation and based on in-house validation data of 150 test samples, the  CDSCO has granted permission to ERLYSIGN to proceed with large-scale clinical trials, said the startup in a statement.

Notably, during the initial studies, ERLYSIGN's active salivary biomarker study showcased remarkable performance, demonstrating a sensitivity of 98% and an unparalleled specificity of 100%.

The proprietary technology developed by ERLYSIGN promises to revolutionise cancer detection through its advanced approach. Patents has been secured in both the United States and India for its Oral Cancer detection kit while Lung Cancer Detection Kit awaits the patent nod.

The oral cancer detection kit streamlines the testing process, allowing multiple tests to be processed within a mere 15-20 minutes, it said.

"Our mission at ERLYSIGN is to provide an easy, accurate, affordable, and painless solution for early cancer detection," says CEO of ERLYSIGN Shubhendra Singh Thakur, "Our active salivary biomarker study, now approved by CDSCO, marks a significant step towards achieving this goal. With our technology, individuals can now detect precancerous conditions even before the appearance of any oral lesion or tumour formation, empowering proactive intervention and potentially saving countless lives” he further added.